Navigation Links
CureDM Awarded 2009 Diabetes Product Innovation of the Year by Frost and Sullivan
Date:9/9/2009

WYNNEWOOD, Pa., Sept. 9 /PRNewswire/ -- CureDM, Inc., a biopharmaceutical company dedicated to developing novel therapeutic approaches to Diabetes Mellitus, announced today that CureDM has been chosen as the recipient of Frost and Sullivan's Technology Innovation Award for 2009 for its development of Pancreate(TM), a human peptide therapeutic. The 2009 North American Diabetes Mellitus Therapeutics Excellence in Healthcare Product Innovation of the Year Award is bestowed upon a company that has carried out research, which has resulted in innovations that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award also recognizes the quality and depth of a company's R&D program, as well as the vision and risk-taking to undertake such an endeavor.

"We are extremely proud to have been selected for such a prestigious award by this independent process directed by Frost and Sullivan's analyst team. Being recognized as the product innovation of the year in the challenging field of diabetes is a testament to the unwavering commitment of the CureDM team to impact the underlying pathology of diabetes," said H. Joseph Reiser Ph.D., President and Chief Executive Officer of CureDM.

CureDM's lead product candidate, Pancreate(TM) addresses the increasing unmet need in the treatment of diabetes which is projected to grow to 300 million patients worldwide by 2030 at alarming treatment costs. While extensive resources and efforts are being applied to identify new treatment approaches, the therapeutic portfolio for diabetes is currently challenged by the lack of technologies that target the underlying disease process. In this regard, evolving diagnostic data for both, type 1 and type 2 diabetes reveals that an important causative aspect of the disease is the substantial reduction e.g. 50-80% in pancreatic structures called islets, which contain all of the hormone secreting cell types required for normal glucose metabolism, only one of which is the beta cell type that secretes insulin. Replacement of insulin alone does not reverse the pathological state.

CureDM's technology, Pancreate(TM) targets this causative aspect of the disease by its inherent mechanism of action to repopulate the pancreas with new islet structures by a process known as islet neogenesis. Based on animal and isolated human tissue studies, reestablishment of new islet structures can occur in as little as 2-3 weeks of treatment with Pancreate(TM) resulting in concomitant reduction or elimination of insulin requirements. The company was awarded a Composition of Matter patent in 2008 by the USPTO for the structure and use of Pancreate(TM) in diabetes and related disorders.

"By working to reverse the disorder, CureDM's Pancreate(TM) is a fine example of innovation and forward thinking in the way we go about treating diabetes today," said Frost & Sullivan's K.N. Prema.

Pancreate(TM) is currently in late stage preclinical development and is expected to enter clinical trials in early 2010 for both, type 1 and type 2 diabetic patients.

About CureDM

CureDM is a biopharmaceutical company focusing on Diseases of Metabolism. CureDM has developed a proprietary platform technology using genomics and proteomics to identify bioactive components of gene products that are fundamental to address unmet medical needs. CureDM's initial focus is in the therapeutic areas of diabetes and obesity. Pancreate(TM) also known as Human proIslet Peptide (HIP) is a 14-amino acid, stabilized human peptide that stimulates the signal pathways that induce new islet formation in the pancreas, without the use of stem cells. Pancreate(TM) creates new insulin-producing beta cells by generating new islets that contain alpha, beta, gamma and delta cells, all of which are necessary to regulate glucose metabolism. Pancreate is the first product derived from this process, and other pipeline compounds are under development. CureDM, Inc. is located in the Lankenau Institute for Medical Research (LIMR) at the Lankenau Hospital campus in Wynnewood, PA. LIMR has supported and collaborated with CureDM on several studies involving its technology. For additional information please visit: www.limr.org and www.curedm.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com. For additional information on the Best Practices Awards, please visit www.awards.frost.com.


'/>"/>
SOURCE CureDM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
3. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
4. PartsSource Awarded US Patent for PartsFinder(TM) Application
5. Wrigleys Orbit(R), Extra(R) and Eclipse(R) Sugar-Free Chewing Gums Awarded American Dental Associations Seal of Acceptance
6. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
7. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
8. UMASS Medical School awarded National Childrens Study contract
9. beBetter Awarded WV Quitline Contract
10. Henricksen Awarded 2007 Distinguished Veterinary Staff Award
11. Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... of Proctology) announced today the opening of 3 medical offices specializing specifically ... Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, ...
(Date:1/18/2017)... ... 18, 2017 , ... A recent video posting of a new fidget product ... of fidgeting to relieve stress and anxiety. No one was more surprised than ... had just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: